Evidence map›Paper›PMID 33498207›Full record

ArticleDentistry journal2021

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients.

Christian Bacci, Alessia Cerrato, Virginia Dotto, Renato Zambello, Gregorio Barilà, Albana Liço, Gianpietro Semenzato, Edoardo Stellini, Gastone Zanette

Open access · goldAbstract read
In one paragraph

Article in Dentistry journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Christian BacciClinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.ORCID 0000-0002-6956-6227
Alessia CerratoClinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.
Virginia DottoClinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.
Renato ZambelloDepartment of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.
Gregorio BarilàDepartment of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.
Albana LiçoDepartment of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.
Gianpietro SemenzatoDepartment of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.
Edoardo StelliniClinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.
Gastone ZanetteClinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.ORCID 0000-0003-0110-1017
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Multiple myeloma is a rare cancer that primarily affects the bone marrow. Osteoclasts are responsible for increased bone resorption and, therefore, bone destruction. Bisphosphonates are a class of drugs that can slow down bone resorption by reducing the number and action of osteoclasts. Intravenous injections of bisphosphonates (generally Zoledronic Acid) are administered to patients affected by Multiple Myeloma, but BRONJ is described as a serious side effect. This 5-year retrospective study aims to evaluate the efficacy of appropriate dental treatment protocols prior to initiating bisphosphonate therapy to prevent the development of BRONJ. (2) Methods: A total of 99 patients with symptomatic multiple myeloma were involved in this study (41-90 years, mean age 65 years, standard deviation 5 years). The data relating to the visits were tracked using a specific server and consulting the clinical reports. The AAOMS (American Association of Oral and Maxillofacial Surgeons) position was applied for both diagnosis and treatment. A total of 79 patients were examined before the administration of bisphosphonates (group A) and 20 after (group B). (3) Results: The entire sample required dental treatment: 23.2% underwent restorative therapy, 8% endodontic treatments, 44.4% tooth extractions. Periodontal disease was present in 41.4% of the patients. No osteonecrosis was observed in the first group, whereas BRONJ was found in five patients of the second one (25%) and two patients (10%) showed osteosclerotic areas under investigation [OR 0.026 (CI 0.0027 to 0.2454)]. (4) Conclusions: In the literature, there are no precise data about the prevalence of BRONJ. Despite the limitation of the present study, we point out that dental treatment before the treatment with intravenous bisphosphonates can help in reducing the incidence of BRONJ and good dental status is necessary for BRONJ prevention.

Indexed as

bisphosphonatesBRONJMRONJmyelomaONJosteonecrosis

Identifiers

PMID33498207
PMCPMC7908966
OpenAlexW3122641549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.